Accessibility Menu
Virpax Pharmaceuticals logo

Virpax Pharmaceuticals(OTC) VRPX

Market Cap$100.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-100%
5 Year-100%
1 Year-99%
1 Month-99%
$0.00
+0.00%
+0.00Today
Virpax Pharmaceuticals last closing stock price
MetricPriceDate
Last closeUSD 0.002026-08-12
Virpax Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.002026-08-04
1 month-99.1%USD 0.012026-07-13
3 month-75%USD 0.002026-05-14
Year to date-99.1%USD 0.012025-12-31
1 year-99.09%USD 0.012025-08-12
3 year-100%USD 220.002023-08-11
5 year-100%USD 1,132.502021-08-13
Since inception-100%USD 1,632.502021-02-17

Virpax Pharmaceuticals Financials at a Glance

Market Cap

$100.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$12.07M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-1091.50 (Low)

Price

$0.00

Volume

3,402

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.10

Estimated Earnings Date

Aug 11, 2026

VRPX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Virpax Pharmaceuticals

Virpax Pharmaceuticals, Inc. specializes in developing innovative drug delivery systems for non-opioid pain management and central nervous system disorders. The company's primary focus is on leveraging proprietary technologies to enhance drug efficacy, aiming to address unmet medical needs in pain management.

Products and Services

Envelta: An intranasal spray for delivering enkephalin, aimed at severe pain management and potentially PTSD.

Probudur: A liposomal technology for long-acting bupivacaine designed for postoperative pain management.

NobrXiol: A cannabidiol-based therapy delivered intranasally for treating epilepsy-related syndromes in pediatric patients.

Epoladerm: A topical spray film for managing osteoarthritis pain.

AnQlar: An antiviral nasal spray developed as a barrier against viruses like influenza and SARS-CoV-2.

What Makes Virpax Pharmaceuticals, Inc. Special

Virpax stands out with its focus on proprietary, non-opioid pain management delivery technologies. This approach positions it uniquely in the global pain management market, differentiating it from traditional pharmaceutical companies.

Five Things You Need to Know

Virpax operates as a preclinical-stage company with a focus on novel pain management technologies.

The company is advancing several proprietary delivery technologies, including intranasal and liposomal systems.

Virpax holds exclusive global rights to patented technologies used for non-opioid pain treatments.

The company's strategic growth is supported by collaborations with established research institutions and commercial partnerships.

Virpax's future success hinges on securing regulatory approvals and commercializing its product candidates.

AI Generated • Apr 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

2

CEO

Jay Dhaliwal

Website

www.virpaxpharma.com

Headquarters

Berwyn, PA 19312, US

VRPX Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-2364.82%

Return on Capital

N/A

Return on Assets

-775.72%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$100.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.24M

Volume

3.40K

Avg. Volume

458.524

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$12.08M

EBITDA

-$8.75M

Operating Cash Flow

-$16.71M

Capital Expenditure

$0.00

Free Cash Flow

-$16.71M

Cash & ST Invst.

$1.51M

Total Debt

$0.00

Virpax Pharmaceuticals Performance Analysis

Virpax Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 0N/A
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
Virpax Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12024-03-31N/A
Q22024-06-30N/A
Q32024-09-30N/A
Q42024-12-31N/A
Virpax Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -257.28N/A
20222022-12-31USD -462.1479.6%
20232023-12-31USD -324.22-29.8%
20242024-12-31USD -70.91-78.1%
Virpax Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12024-03-3129.3%
Q22024-06-3036.4%
Q32024-09-3075.4%
Q42024-12-31-86.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2024YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$100.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$50.00

N/A

Employees

2

N/A

Net Income

-$3.39M

+25.7%

EBITDA

-$3.39M

+25.7%

Quarterly Fundamentals

Name
Q4 2024YOY CHG

Total Cash

$1.51M

-83.4%

Total Debt

$0.00

N/A

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-7.76%

N/A

Return on Invested Capital

13.22%

N/A

Free Cash Flow

-$2.87M

+4.7%

Operating Cash Flow

-$2.87M

+4.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SLXNWSilexion Therapeutics Ltd.
$0.01-35.00%
SYRSSyros Pharmaceuticals, Inc.
$0.00+400.00%
VINCVincerx Pharma, Inc.
$0.01+0.00%
PPBTPurple Biotech Ltd.
$1.48-7.50%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$146.15+0.10%
SMCISuper Micro Computer
$37.61+0.19%
INTCIntel
$100.95+0.03%
NOKNokia
$10.32+0.09%

Questions About VRPX

What is the current price of Virpax Pharmaceuticals?

Virpax Pharmaceuticals is trading at $0.00 per share.

What is the 52-week range for Virpax Pharmaceuticals?

Over the past 52 weeks, Virpax Pharmaceuticals has traded between $0.00 and $0.10.

How much debt does Virpax Pharmaceuticals have?

As of the most recent reporting period, Virpax Pharmaceuticals reported total debt of $0.00.

How much cash does Virpax Pharmaceuticals have on hand?

Virpax Pharmaceuticals reported $1.51M in cash and cash equivalents in its most recent financial results.

What is Virpax Pharmaceuticals’s dividend yield?

Virpax Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services